Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Profile Name||MLH1 inact mut|
|Gene Variant Detail|
|Relevant Treatment Approaches|
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|MLH1 inact mut||colorectal cancer||not applicable||N/A||Preclinical||Emerging||In a preclinical study, MLH1 inactivation through hypermethylation was associated with high microsatellite instability (MSI-H) colorectal carcinoma by whole genome sequencing of tumor samples (PMID: 22810696), suggesting it may be a potential biomarker.||22810696|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02912559||Phase III||Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin||Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair||Recruiting|
|NCT03375307||Phase II||Olaparib||Olaparib in Treating Patients With Metastatic or Advanced Urothelial Cancer With DNA-Repair Defects||Recruiting|
|NCT04019964||Phase II||Nivolumab||Nivolumab in Biochemically Recurrent dMMR Prostate Cancer||Recruiting|
|NCT04019327||Phase Ib/II||Talazoparib + Temozolomide||A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer||Recruiting|
|NCT04104893||Phase II||Pembrolizumab||A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation (CHOMP)||Recruiting|